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Referee #1 (Remarks to the Author):
A central model of the Spindle Assembly Checkpoint (SAC)originally proposed by the Musacchio lab is the "template model" of Mad2 that proposes that the Mad1:C-Mad2 complex acts as a generator of Mad2 conformers that can inhibit Cdc20. In this study by Fava et al the role of the closed conformation of Mad2 (C-Mad2) in the SAC is investigated using a monoclonal antibody that specifically recognizes this form of Mad2. Following a careful characterization of the antibody with specific conformers of Mad2 they use the antibody to show that the closed form of Mad2 is only present on kinetochores during an active SAC and this is likely due to p31/comet dependent capping. The authors also show that Mad1:C-Mad2 is the only source of closed Mad2 throughout the cell cycle while Cdc20:C-Mad2 exists only during an active checkpoint. Finally antibody injections combined with time-lapse imaging are used to show that it is unlikely that Mad2 plays a separate function as a mitotic timer in addition to its role in the SAC. Overall I found the paper well written and easy to read and the experiments are nicely done and of high quality. I am more concerned on the novelty of some of these findings since the experiments mainly confirm results already obtained with Mad2 mutants specifically locked in one conformer (Nezi et al 2006 , De Antoni 2005 both these studies provide in vivo evidence for the template model) and experiments with Mad1 (Chung E and Chen R, 2002) . Of most interest and novelty is the capping function of p31 which they provide evidence is on-going during an active SAC but insight into how the interaction between p31 and Mad1:C-Mad2 is regulated would increase the interest of the paper. Particular evidence that p31 is actually localizing to the kinetochore during an active SAC would be needed to support their model and evidence for this would be beneficial. In addition the result of a continued role for Mad1 in sustaining the SAC signal is of significance as it indicates that part of the template model (the cytoplasmic amplification) proposing that cytosolic Cdc20-Mad2 can act as an amplifier for the SAC might not be correct.
Specific comments/experiments I think should be performed.
1) The authors should include the Nezi et al paper 2006 in their reference and discuss their results in relation to their own results. 2) In figure 1C include a blot for Mad1 and Cdc20. 3) In figure 2 the blot of the p31 knockdown efficiency should be moved from the supp figure and also include blots for Mad1 and Mad2 to show that the levels of these proteins are not affected by p31 knockdown. 4) In figure 2C the authors uses the increased intensity of CM2(276) staining at the centrosomes upon p31 knockdown to suggest that p31 is capping the Mad1:C-Mad2 complex on this structure. However what is clear is also that the levels of Mad1 increases a lot on the centrosome upon p31 knockdown. A careful quantification of pixel intensity is required to reach this conclusion. 5) It is proposed that Mad1:C-Mad2 is the major source of closed Mad2 and that during an active SAC the capping function of p31 is diminished. However their Mad1 IPs in Fig S4 indicates a constant level of p31 in association with Mad1. The authors should comment on this. 6) In relation to the staining with CM2(276) have different fixation protocols been tested and do they give the same result. Authors should provide some discussion of this as different protocols can give different results. 7) In figure 2A-C and 2F a panel with the Mad2 antibody recognizing all Mad2 forms should be included. Figure 2F is based on very high levels of p31 overexpression. I think it would be beneficial to establish the ratio of endogenous Mad2 and p31 to evaluate how much p31 is being produced compared to Mad2. It would also help understand why the p31 gelfiltration profiles hardly change between nocodazole and MG132. As the authors have recombinant proteins available this should be possible. 9) In figure 3 I think it would be beneficial to include the panel G from Fig S4 so This manuscript by Fava et al. reports on the in vivo validation of the idea that the Mad2 checkpoint protein adopts two functionally different conformers. Structural studies showed that Mad2 can adopt two conformer states that are termed Open and Closed. The C-conformer is selectively bound to ligands such as Mad1, Cdc20 and p31 Comet. Complexes of Mad1:C-Mad2 and Cdc20:C-Mad2 are capable of catalytically converting O-Mad2 to the biochemically active C-Mad2. C-Mad2 binds to Cdc20 and sequesters it away, and thus prevents activation, of the APC/C. These in vitro findings have led to the template model for how a single unattached kinetochore can generate a signaling cascade to inhibit the cellular pool of APC/C. Although mutants have been identified that adopt O or C conformations, a major caveat of the template model is that it lacked direct evidence that endogenous Mad2 adopts different conformational states. This paper describes the isolation of a monoclonal Mad2 antibody that selectively recognizes the C-Mad2 conformer in vivo. The authors present convincing evidence that the CM2-276 mAb clone specifically recognizes the C-conformer. First, CM2-276 can selectively immunoprecipitate Mad2 complexes, but not free Mad2, from cell lysates. The mAb also does not recognized denatured Mad2 epitopes. Specificity was directly demonstrated by using recombinant Mad2 mutants that are locked in either O or C states. To test if CM2-276 recognized the dimerization interface, which is what is different between O and C conformers, they conducted a titration experiment that tested the ability of CM2-276 to compete with p31 comet, a protein known to selectively bind the dimerization surface of C-Mad2. A similar experiment was also conducted by using a O-confomer Mad2 mutant that normally binds to C-Mad2. Under both conditions, CM2-276 competed with both p31 and the O-Mad2 mutant for binding to the C-Mad2. Lastly, they showed that CM2-276 failed to bind to a dimerization defective Mad2 mutant. Collectively, the authors provide compelling evidence that they have generated a C-conformer specific Mad2 mAb. CM2-276 was then used to probe for Mad2 conformational states as a function of its subcellular localization and interactions with protein complexes at different cell cycle stages. Staining showed that CM2-276 stained kinetochores in prophase through prometaphase but failed to stain NPC, or the poles, where Mad2 is known to co-localize with Mad1. The lack of C-Mad2 reactivity at poles and NPC was due to masking by p31Comet, as CM2-276 staining was restored when endogenous p31 comet was depleted by siRNA. Staining of Kts could be masked in cells overexpressing p31Comet, but not a mutant that is unable to bind to C-Mad2. This provides the first in vivo evidence of the existence of C-Mad2 conformer. Endogenous Mad2 is known to form multiple protein complexes that have been proposed to represent different parts of the checkpoint signaling cascade. Using the CM2-276 mAb, the authors tested how C-Mad2 was distributed amongst these complexes. Lysates were prepared from cells arrested in by thymidine, nocodazole, and MG132, that represented G1/S, spindle checkpoint arrested mitosis, and spindle checkpoint silenced metaphase, respectively. Lysates were fractionated by gel filtration to separate Mad2 free and complexes. Consistent with the notion that C-Mad2 conformer specifies interactions with other proteins, CM2-276 reactivity was only detected in fractions containing Mad2 complexes whereas no reactivity was detected for the fractions containing free, and thus O Mad2 conformer. In the interphase extracts, C-Mad2 was associated only with Mad1, but not with Cdc20. In spindle checkpoint arrested extracts, C-Mad2 was complexed to both Mad1 and Mad2, as seen in checkpoint silenced extracts. Using siRNA knockdown of Mad1, they showed that formation of C-Mad2 in interphase cells depended on the presence of its ligand. Micoinjection of CM2-276 into nocodazole arrested cells promoted mitotic exit, thus leading the authors to conclude that the C-Mad2 is functionally relevant in vivo. They next conducted microinjection experiments into non-drug treated cells to test if disrupting C-Mad2 altered mitotic timing, as was proposed for Mad2 function. Indeed, cells injected with CM2-276 accelerated through mitosis with lagging chromosomes, as was shown in published studies using regular Mad2 antibodies. They then tried to discern whether Mad1 was also playing a role as a mitotic timer, given its proposed role in generating C-Mad2. This idea conflicts with published siRNA experiments that showed cells depleted of Mad1 did not accelerated out of mitosis, in contrast to when Mad2 was depleted. The authors compared mitotic progression in cells injected with CM2-276 or a Mad1 mAb and found no difference. They conclude Mad1 is also part of the mitotic timer. They further tested the consequence of chemical inhibition of the Mps1 kinase, which lies upstream of Mad1 and Mad2 and found cells also accelerated out of mitosis. These findings challenges the existence of a mitotic timer, which is proposed to act independently of the checkpoint or more accurately, the status of the kinetochore. The strength of this paper is the discovery of a C-Mad2 specific monoclonal antibody as this provided the critical tool to validate the existence of different Mad2 conformers in cells. Up till now, only mutants that adopt various different conformational states have been available to test the functional importance of the C-and O-conformers. The antibody clearly showed that only the C-Mad2 was present in complexes, and that the C-Mad2 was also enriched at the NPC, spindle poles and kinetochores. The antibody and chemical inhibitor studies refutes the existence of an intrinsic mitotic timer, that acts independently of the checkpoint. The conclusions are very solid and make an important contibution to the field.
8) The results in
Referee #3 (Remarks to the Author):
The production of an anaphase inhibitor by the SAC is initiated by unattached kinetochores. Key in our understanding of how kinetochores can catalyse this production was the finding that Mad2 dimerises at kinetochores and undergoes a conformational change when bound to Mad1/Mad2 dimers in vitro, that allows it to bind Cdc20. This implies that a conformational change at kinetochores creates a Mad2 species that is essential for anaphase inhibition. Important question remained: is this conformational change important for the spindle assembly checkpoint in cells, and how can Mad2 participate in the proposed timer in interphase when unattached kinetochores are absent? This study by Fava et al now use a conformation-specific mAb to C-Mad2 to address these issues. The authors find that C-Mad2 is required for initiation and maintenance of the SAC, and that Mad1 inhibition has the same timing phenotype as inhibition of C-Mad2.
I'm very enthusiastic about this well-written, experimentally well-executed manuscript, as it lends strong support to a model (O-to C-Mad2 conversion at kinetochores is critical for SAC function) that has become widely accepted in the field but was never proven to occur in cells. Moreover, the puzzling observations by Meraldi et al about the distinction between timer and SAC that created conceptual problems when considering how this timer and the SAC operate molecularly, are convincingly challenged by this study.
I have only minor comments: 1. Since critical conclusions are based on the Ab-injection experiments, it's important to show that effects are not due to the possibility that high concentrations of Ab in the cells cause unspecific effects. Much like the fact that phospho-specific antibodies start to bind unphosphorylated epitope when added in excess, the C-Mad2 antibody may start to bind O-Mad2 when added in excess. Simple immunofluorescence to detect the injected antibody will be able to tell whether the amount of injected Ab can be reduced to a level that preserves strong kinetochore levels of the injected Ab. Also, pre-adsorption with recombinant C-Mad2 will control for other possible aspecific effects of the injected solution on the SAC. 2. Maciejowski et al is not the first nor only paper that showed Mps1's involvement in mitotic timing. The papers by the Taylor and Musacchio labs that appeared simultaneously with the Maciejowski study also showed accelerated mitosis upon Mps1 inhibition, but the first evidence in fact was a study by Sliedrecht et al in PLoS ONE, appearing a few months earlier. These studies should be acknowledged. Thank you very much for your positive reply. We thank our referees for their constructive comments to our original manuscript (EMBOJ-2011-77694 ). Here we now submit the revised version of this manuscript, entitled "Probing the in vivo function of Mad1:C-Mad2 in the spindle assembly checkpoint" for publication in Embo Journal. All issues raised by the reviewers have been addressed in the revised version, as summarized below and detailed in the accompanying reply to the reviewers' comments. With regard to the points raised by reviewer 1, we provide now evidence that p31comet does localize to kinetochores during an active SAC: expression of sub-endogenous levels of Myc-p31cometWT allowed its detection at KTs (new Figure 3) . Importantly, Mad2 siRNA abolished p31comet signal at KTs, showing that p31comet localizes to KTs in a Mad2-dependent manner ( Figure 3C ). Another important point raised by this reviewer was the examination by immunofluorescence of all Mad2 forms, as done for C-Mad2 in Figure 2 . For that, we utilized a HeLa-Kyoto cell line stably expressing LAPGFP-mouse-Mad2, effectively recognized by CM2276 ( Figure S4A ) and previously shown to be functionally proficient (Hübner et al., 2010) . LAPGFPmouse-Mad2 co-localized with Mad1 throughout the cell cycle ( Figure S4B-C) , further strengthening the notion that the absence of CM2276 staining at NPCs and spindle poles does not reflect absence of C-Mad2 but rather masking by p31comet. p31comet depletion did not change the LAPGFP-mouse-Mad2 signal detected at NPCs or spindle poles, but it significantly increased the LAPGFP-mouse-Mad2 signal detected at KTs (new Figures 2G and S4B-C) . These data suggest that additional Mad2, almost certainly in the open conformation, had been recruited upon depletion of p31comet, implying that asymmetric dimer formation is differentially regulated at KTs. In addition, upon high p31comet overexpression, not only C-Mad2 (detected by CM2276) but also LAPGFPmouse-Mad2 signal appeared absent from kinetochores (not shown). This result prompted us to deplete former Figure 2F , as this is no longer relevant to our argument. Finally, we have included all control data requested by this reviewer, modified our Figures and included references according to his/her requests, as detailed in our point per point reply.
Regarding reviewer 3, we have extended our microinjection analysis to rule out any potential cross-reactivity of CM2276 towards O-Mad2. In particular, we show that co-injection of CM2276 with O-Mad2 had minor or no impact on the neutralizing power of CM2276, whereas preincubation with C-Mad2 almost completely abolished the nocodazole override observed upon CM2276 injection (new Figure S6 ). These data show that CM2276 exclusively targets C-Mad2 when microinjected in our experimental conditions.
Having addressed all concerns of the reviewers, we hope that our revised manuscript will now be acceptable for publication and we look forward to your positive response.
Reply to reviewer's points:
Reviewer #1: Particular evidence that p31 is actually localizing to the kinetochore during an active SAC would be needed to support their model and evidence for this would be beneficial.
We agree with the reviewer that the presence of p31comet at KTs during an active SAC would further strengthen our model. Data presented in our original manuscript led to the strong prediction that p31comet should localize at kinetochores even during an active SAC and this localization should be at least partly Mad2-dependent. In order to visualize p31comet at kinetochores, we expressed "p31cometWT" and "p31cometQAFA" under the control of an SV40 promoter. This allowed the expression of our Myc-tagged constructs at sub-endogenous levels (new Figure 3A) . Following cytosolic pre-extraction, Myc-p31WT, but not Myc-p31cometQA-FA (carrying mutations that abolish Mad2 binding), became detectable at kinetochores. Furthermore, localization of p31comet at KTs depends on Mad2 as Mad2 siRNA-mediated depletion completely abolished the KTs staining of Myc-p31cometWT (new Figure 3C) . These new results provide evidence for Mad2-dependent localization of p31comet at KTs even during an active SAC and have been included and discussed in the revised version of the manuscript.
Specific comments: 1) The authors should include the Nezi et al paper 2006 in their reference and discuss their results in relation to their own results.
This important reference has been now included in the revised manuscript.
2) In figure 1C include a blot for Mad1 and Cdc20.
Mad1 and Cdc20 blots are displayed in Figure S1D . The rabbit Mad2 antibody used in this study could readily immunoprecipitate p31comet in lysates from cells with both an active and an inactive SAC (as shown now in Figure S1D and in line with what we observed in Mad1 IPs, Figure S5A ). However, neither Mad1 nor Cdc20 could be co-precipitated by this antibody ( Figure S1D ). Importantly, we have noticed that this Mad2 rabbit polyclonal Ab had been raised, according to the producer¥s data sheet, against a peptide mapping within the last 55 residues of Mad2 that include the "seat belt" region, necessary for binding to Mad1 and Cdc20. Therefore, it is very likely that the lack of precipitation of Mad2¥ ligands by this antibody is due to competition. Note that we now specify that the absence of preference of this antibody for Mad2 conformers ( Figure 1A ) applies to western blot (i.e. denaturing conditions) experiments.
3) In figure 2 the blot of the p31 knockdown efficiency should be moved from the supp figure and also include blots for Mad1 and Mad2 to show that the levels of these proteins are not affected by p31 knockdown.
The above mentioned blots have been performed and are now displayed in Figure 2B . Indeed p31comet siRNA-mediated depletion did not affect Mad1/Mad2 protein abundances.
4) In figure 2C the authors uses the increased intensity of CM2(276) staining at the centrosomes upon p31 knockdown to suggest that p31 is capping the Mad1:C-Mad2 complex on this structure. However what is clear is also that the levels of Mad1 increases a lot on the centrosome upon p31 knockdown. A careful quantification of pixel intensity is required to reach this conclusion.
We thank the reviewer for pointing this out. As suggested, we have quantified the pixel intensities of the Mad1 signal in 40 individual spindle poles from both control and p31comet-depleted cells. These new data showed that the Mad1 intensity at spindle poles does not vary in response to p31comet depletion (p-Value for Student¥s t-Test of 0.82, data not shown). We have therefore replaced the panels originally displayed with more representative ones (see new Figure 2D ). Fig S4 indicates We had previously commented on this unexpected observation in the Discussion section (manuscript page 23); in the revised manuscript, we now refer to this in the Results section as well (manuscript pages 13-14).
5) It is proposed that Mad1:C-Mad2 is the major source of closed Mad2 and that during an active SAC the capping function of p31 is diminished. However their Mad1 IPs in

6) In relation to the staining with CM2(276) have different fixation protocols been tested and do they give the same result. Authors should provide some discussion of this as different protocols can give different results.
In addition to PTEMF (formaldehyde-based) fixation, methanol fixation has been now tested. Methanol fixation resulted in an overall much weaker Mad1 and C-Mad2 signal than that obtained after PTEMF fixation, so that not even Mad1 could be detected at spindle poles. At NPCs, some CMad2 signal overlapped with Mad1, suggesting that methanol fixation does not preserve the p31comet-dependent masking as well as PTEMF fixation (see new Figure S3 ). These results are now mentioned in the manuscript (see Legend to Figure S3 ).
7) In figure 2A-C and 2F a panel with the Mad2 antibody recognizing all Mad2 forms should be included.
To the best of our knowledge, none of the polyclonal antibodies available for Mad2 (commercial or otherwise) has been thoroughly characterized as pan-Mad2 Ab. Furthermore, preference for a conformer and/or reactivity towards epitopes that allows exclusively recognition of a fraction of total Mad2 within cells are not unexpected (our response to point 2 in this document and data published in Hewitt et al., J Cell Biol 2010 are examples for this). Therefore, as an alternative approach to address this point, we utilized a HeLa-Kyoto cell line stably expressing LAPGFP-mouse-Mad2 (previously published in Poser et al., Nat Methods 2008 and H¸bner et al., Chromosoma 2010) and visualized Mad2 by monitoring GFP fluorescence. Importantly, LAPGFP-mouse-Mad2 was functionally proficient (as shown in H¸bner et al. 2010) , strongly suggesting that it displays the same localization as endogenous Mad2. In addition, the mouse homologue of Mad2 could be effectively recognized by CM2276 (Figure S4A ), suggesting the absence of detrimental effects on Mad2 recognition by CM2276 in this cell line. LAPGFPmouse-Mad2 co-localized with Mad1 both at NPCs and spindle poles ( Figure S4B-C) , further strengthening the notion that the absence of CM2276 staining at NPCs and spindle poles does not reflect absence of C-Mad2 but rather masking by p31comet. p31comet depletion did not change the LAPGFP-mouse-Mad2 signal detected at NPCs or spindle poles, although it significantly increased LAPGFP-mouse-Mad2 signal detected at KTs (new Figures 2G and S4B-C) . These data show that although the dimerization interface of C-Mad2 undergoes masking by p31comet at NPCs, KTs and spindle poles, unmasking of this interface by p31comet removal leads to increased recruitment of Mad2 (presumably in its open conformation) selectively at kinetochores, arguing that asymmetric dimer formation is differentially regulated at KTs. These new data are discussed in the revised manuscript. Figure 2F is based on very high levels of p31 overexpression. I think it would be beneficial to establish the ratio of endogenous Mad2 and p31 to evaluate how much p31 is being produced compared to Mad2. It would also help understand why the p31 gel filtration profiles hardly change between nocodazole and MG132. As the authors have recombinant proteins available this should be possible.
8) The results in
We utilized recombinant Mad2 and p31comet to establish the relative abundance of the endogenous proteins in a cell lysate and conclude that p31comet is approximately twice as abundant as Mad2 (new Figure S5B) . Based on this, we estimate that the overexpression of Myc-p31comet under the control of a CMV promoter as shown in the old Figure 2F produced amounts of p31comet corresponding to 150 times the amount of endogenous Mad2 at a single transfected cell level (data not shown). When performing CM2276 staining in these conditions (previous Figure 2F) , we described the absence of CM2276 kinetochore staining, despite the presence of Mad1. In our original manuscript we interpreted the above result as complete masking of the C-Mad2 dimerization interface at kinetochores. However, while addressing point 7 raised by this reviewer, we noticed that LAPGFP-mouse-Mad2 appeared also absent from kinetochore in the same p31comet overexpression conditions (data not shown) prompting us to reconsider the above interpretation. It appears now likely that when p31comet is highly overexpressed, it can also interfere with the ability of Mad2 to bind Mad1 (presumably by sequestering the protein in the cytoplasm during turnover). In light of this new finding we decided to remove the former Figure 2F , as the original purpose of this experiment was to obtain complete masking of the dimerization interface of C-Mad2 as a complementary approach to the unmasking effect observed upon p31comet siRNA. We are thankful to this reviewer for bringing up a comment that led to this important correction. For the sake of conciseness and consistency, we decided to also remove the Figure in which we initially showed competition with O-Mad2 (by Mad2 C overexpression), i.e. the former Figure S3 . As suggested by this reviewer, the semi-quantitation of Mad2/p31comet protein abundances ( Figure  S5B ) is now used to discuss the SEC elution profile of p31comet and Mad2. Briefly, the fact that p31coment is twice as abundant as Mad2, and yet is undetectable by Western blotting in the SEC fractions where C-Mad2 elutes, supports the notion that only a very minor fraction of p31comet is interacting with Mad2 in the high molecular weight pool. Fig S4 so Following the reviewer's suggestion, we performed experiments aimed at assessing potential crossreactivity of CM2276 towards O-Mad2. We therefore tested the SAC-neutralizing power of CM2276 when co-injected with PBS alone or with recombinant O-/C-Mad2 (using an antibodyantigen molar ratio of 1:2). Whereas co-injection of CM2276 with O-Mad2 had little or no impact on the neutralizing power of CM2276, co-injection with C-Mad2 almost completely abolished the phenotypic consequences of CM2276 injection, i.e. nocodazole override (new Figure S6A-B) . These data strongly support the notion that CM2276 exclusively targets C-Mad2 when microinjected in our experimental conditions. The fact that CM2276 and Mad1 mAb microinjection phenotypes led to nearly identical phenotypes in a number of assays, further strengthens our conclusion that CM2276 exclusively recognizes C-Mad2 in those assays. We apologize for this omission. These references have now been included.
9) In figure 3 I think it would be beneficial to include the panel G from
Maciejowski et al is not
Acceptance letter 27 June 2011
Thank you for submitting your revised manuscript for our consideration. It has now been seen once more by one of the original referees (see comments below), and I am happy to inform you that there are no further objections towards publication in The EMBO Journal.
You shall receive a formal letter of acceptance shortly.
Yours sincerely, Editor The EMBO Journal ___________________________________ Referee #1
(Remarks to the Author) In the revised manuscript by Fava et al all the points I raised to the first manuscript has been very carefully addressed both experimentally and in the manuscript. The new data showing p31 on the kinetochore adds nicely to the story as does the measurements of p31 and Mad2 in extracts. I think this paper is now a work of very good quality and well written and should be published in EMBO Journal without further modifications.
